Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by doctordeaconon Jan 18, 2017 7:40pm

82 Views

Post# 25725708

RE:WERE RICH PEOPLE congratulations!!!!

if we do 24 million in revenues the price to earnings ratio based on current share-structure is $3.00 ,i think we will do 8 million in revenue so the model price based on chartered accountants would be $1.00 but we have a share- buy back so we will reserve model pricing new farms.

Bullboard Posts

Debt-free cannabis company set for next stage of growth